RECRUITING

HIIT Following Breast Cancer Chemotherapy

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Chemotherapy is an effective breast cancer treatment, which helped to increase the 5-year survival rate to approximately 95%. However, breast cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect and durability of a novel high-intensity interval training compared to moderate-intensity continuous training on cardiovascular rehabilitation in breast cancer survivors.

Official Title

High Intensity Interval Training: Optimizing Exercise Therapy to Mitigate Cardiovascular Disease Risk Following Breast Cancer Chemotherapy

Quick Facts

Study Start:2024-03-07
Study Completion:2026-05-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05913713

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 85 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * female patients based on biological sex
  2. * 18 to 85 years of age
  3. * diagnosis of primary, invasive, non-metastatic, stages I-III breast cancer
  4. * completed chemotherapy for breast cancer (anthracycline, alkylating agent and/or taxane) more than 6 months but less than 18 months prior to study enrollment. Adjuvant endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy, and bisphosphonates are allowed within 6 months of study enrollment and during study participation
  5. * absence of contraindications to exercise or to participate in study
  6. * study clinician approval
  1. * do not meet inclusion criteria
  2. * scheduled to receive surgery or radiation therapy during the intervention period
  3. * any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent)
  4. * lymphedema stage ≥2 prior to study enrollment
  5. * are pregnant
  6. * current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)

Contacts and Locations

Study Contact

Demetra Christou, PhD
CONTACT
352-294-1746
ddchristou@ufl.edu

Principal Investigator

Demetra Christou, PhD
PRINCIPAL_INVESTIGATOR
University of Florida

Study Locations (Sites)

Integrative Cardiovascular Physiology Laboratory, University of Florida
Gainesville, Florida, 32611
United States

Collaborators and Investigators

Sponsor: University of Florida

  • Demetra Christou, PhD, PRINCIPAL_INVESTIGATOR, University of Florida

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-03-07
Study Completion Date2026-05-31

Study Record Updates

Study Start Date2024-03-07
Study Completion Date2026-05-31

Terms related to this study

Additional Relevant MeSH Terms

  • Breast Cancer